We provide a description of the diagnostic odyssey for a cohort of children seeking diagnosis of a rare genetic disorder in terms of the time from initial consultation to most recent visit or receipt of diagnosis, the number of tests per patient, and the types of tests received.
Retrospective chart review of 299 children seen at the Alberta Children’s Hospital (ACH) Genetics Clinic (GC) for whom the result of at least one single-gene test, gene panel, or chromosome microarray analysis (CMA) was recorded.
Of 299 patients, 90 (30%) received a diagnosis in the period of the review. Patients had an average of 5.4 tests each; 236 (79%) patients received CMA; 172 (58%) patients received single-gene tests and 34 (11%) received gene panels; 167 (56%) underwent imaging/electrical activity studies. The mean observation period was 898 days (95% confidence interval [CI] 791, 1004). Among patients with visits recorded prior to visiting ACH GC, 43% of the total observation time occurred prior to the GC.
As genomic technologies expand, the nature of the diagnostic odyssey will change. This study has outlined the current standard of care in the ACH GC, providing a baseline against which future changes can be assessed.
Subscribe to Journal
Get full journal access for 1 year
only $41.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Wakap SN. et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28:165–173.
Ferreira CR. The burden of rare diseases. Am J Med Genet A. 2019;179:885–892.
Chae JH, et al. Utility of next generation sequencing in genetic diagnosis of early onset neuromuscular disorders. J Med Genet. 2015;52:208–216.
Kingsmore SF, et al. Adopting orphans: comprehensive genetic testing of Mendelian diseases of childhood by next-generation sequencing. Expert Rev Mol Diagn. 2011;11:855–868.
Shashi V, et al. The utility of the traditional medical genetics diagnostic evaluation in the context of next-generation sequencing for undiagnosed genetic disorders. Genet Med. 2013;16:176–182.
Tsiplova K, et al. A microcosting and cost–consequence analysis of clinical genomic testing strategies in autism spectrum disorder. Genet Med. 2017;19:1268.
Boycott K, et al. The clinical application of genome-wide sequencing for monogenic diseases in Canada: position statement of the Canadian College of Medical Geneticists. J Med Genet. 2015;52:431–437.
Dragojlovic N, et al. The cost trajectory of the diagnostic care pathway for children with suspected genetic disorders. Genet Med. 2020;22:292–200.
Soden SE, et al. Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders. Sci Transl Med. 2014;6:265ra168.
Stark Z, et al. Prospective comparison of the cost-effectiveness of clinical whole-exome sequencing with that of usual care overwhelmingly supports early use and reimbursement. Genet Med. 2017;19:867.
Tan TY, et al. Diagnostic impact and cost-effectiveness of whole-exome sequencing for ambulant children with suspected monogenic conditions. JAMA Pediatr. 2017;171:855–862.
van Nimwegen KJM, et al. The diagnostic pathway in complex paediatric neurology: a cost analysis. Eur J Paediatr Neurol. 2015;19:233–239.
Monroe GR, et al. Effectiveness of whole-exome sequencing and costs of the traditional diagnostic trajectory in children with intellectual disability. Genet Med. 2016;18:949–956.
Thevenon J, et al. Diagnostic odyssey in severe neurodevelopmental disorders: toward clinical whole‐exome sequencing as a first‐line diagnostic test. Clin Genet. 2016;89:700–707.
Palmer EE, et al. Integrating exome sequencing into a diagnostic pathway for epileptic encephalopathy: evidence of clinical utility and cost effectiveness. Mol Genet Genom Med. 2018;6:186–199.
Schofield D, et al. Cost-effectiveness of massively parallel sequencing for diagnosis of paediatric muscle diseases. NPJ Genom Med. 2017;2:1–7.
Oei K, et al. Genetic testing among children in a complex care program. Children. 2017;4:42.
Alberta Children’s Hospital Foundation. Alberta Children’s Hospital Foundation: our hospital. 2020. http://www.childrenshospital.ab.ca/site/PageNavigator/hospital/our_hospital.
StataCorp. Stata statistical software: release 12. 2011, StataCorp LP: College Station, TX.
Dragojlovic N, et al. The cost and diagnostic yield of exome sequencing for children with suspected genetic disorders: a benchmarking study. Genet Med. 2018;20:1013.
Stavropoulos DJ, et al. Whole-genome sequencing expands diagnostic utility and improves clinical management in paediatric medicine. NPJ Genom Med. 2016;1:15012.
This research was funded by a Seed Grant from the Cumming School of Medicine (CSM) and Alberta Health Services (AHS) Clinical Research Fund at the University of Calgary. C.M-I. is funded by an Alberta Innovates Postgraduate Scholarship and a Network of Alberta Health Economists (NOAHE) Fellowship award. D.A.M. is funded by the Arthur J.E. Child Chair in Rheumatology Outcomes Research and a Canada Research Chair in Health Services and Systems Research.
The authors declare no conflicts of interest.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Michaels-Igbokwe, C., McInnes, B., MacDonald, K.V. et al. (Un)standardized testing: the diagnostic odyssey of children with rare genetic disorders in Alberta, Canada. Genet Med (2020). https://doi.org/10.1038/s41436-020-00975-0
- genetic disorders
- diagnostic odyssey